What is Viatris's research and development expense?

Viatris (VTRS) reported research and development expense of $241.48M in Q4 2025.

How has Viatris's research and development expense changed year-over-year?

Viatris's research and development expense increased by 19.4% year-over-year, from $202.18M to $241.48M.

What is the long-term trend for Viatris's research and development expense?

Over 4 years (2021 to 2025), Viatris's research and development expense has grown at a 9.1% compound annual growth rate (CAGR), from $681.00M to $965.90M.

What does research and development expense mean?

Spending on innovation and product development.

Other

Research and development expense

Viatris Research and development expense remained flat by 0.0% to $241.48M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 19.4%, from $202.18M to $241.48M. Over 4 years (FY 2021 to FY 2025), Research and development expense shows an upward trend with a 9.1% CAGR.

Analysis

StatementIncome Statement

SectionOther

CategoryGrowth

SignalContext dependent

VolatilityModerate

First reportedQ1 2020

Last reportedQ4 2025Feb 26, 2026

How to read this metric

Higher spending typically signals a commitment to long-term innovation and future product pipelines, while significant cuts may signal a shift toward short-term profitability.

Detailed definition

This metric captures the investment in creating new products, improving existing technologies, and advancing internal ca...

Peer comparison

Standard metric for technology and hardware firms; highly comparable to R&D spending at peers.

Metric ID: other_research_and_development_expense_excluding_acquire_88a3cd

Historical Data

5 years

	FY'21	FY'22	FY'23	FY'24	FY'25
Value	$681.00M	$662.20M	$805.20M	$808.70M	$965.90M
YoY Change	—	-2.8%	+21.6%	+0.4%	+19.4%

Range$662.20M – $965.90M

CAGR+9.1%

Avg YoY Growth+9.7%

Median YoY Growth+9.9%

Current Streak3 years growth

Research and development expense at Other Companies

PfizerPFE View metric

BiogenBIIB View metric

AbbVieABBV View metric

Johnson & JohnsonJNJ View metric

Gilead SciencesGILD View metric

Vertex PharmaceuticalsVRTX View metric

Frequently Asked Questions

What is Viatris's research and development expense?: Viatris (VTRS) reported research and development expense of $241.48M in Q4 2025.
How has Viatris's research and development expense changed year-over-year?: Viatris's research and development expense increased by 19.4% year-over-year, from $202.18M to $241.48M.
What is the long-term trend for Viatris's research and development expense?: Over 4 years (2021 to 2025), Viatris's research and development expense has grown at a 9.1% compound annual growth rate (CAGR), from $681.00M to $965.90M.
What does research and development expense mean?: Spending on innovation and product development.